Product Description: ML336 is quinazolinone-based inhibitor against venezuelan equine encephalitis virus (VEEV), with IC50s of 32, 20, and 42 nM for VEEV TC-83 CPE , VEEV V3526 CPE, VEEV Wild Type CPE, respectively. ML336 potently inhibits a VEEV-induced cytopathic effect in three strains of the virus (TC-83, V3526, and wild type Trinidad donkey) in the low nanomolar range[1].
Applications: COVID-19-anti-virus
Formula: C19H21N5O3
References: [1]Chung D, et al. ML336: Development of Quinazolinone-Based Inhibitors Against Venezuelan Equine Encephalitis Virus (VEEV). 2012 Dec 17 [updated 2013 Nov 7]. In: Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010–./[2]Donghoon Chung 1, et al. ML336: Development of Quinazolinone-Based Inhibitors Against Venezuelan Equine Encephalitis Virus (VEEV).
CAS Number: 1613465-33-0
Molecular Weight: 367.40
Compound Purity: 99.09
Research Area: Infection
Solubility: DMSO : 33.33 mg/mL (ultrasonic)
Target: Virus Protease